Research Progress of Chaihu Shugan San in the Treatment of Non-alcoholic Fatty Liver Disease
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i2.2313
Abstract
Non-alcoholic fatty liver disease (NAFLD) belongs to the categories of "flank pain" and "liver fetish" in traditional Chinese medicine. The causes of NAFLD are complex, such as obesity, type 2 diabetes, hyperlipidemia, hypothyroidism, hypopituitarism, sleep apnea syndrome, polycystic ovary syndrome, sexual dysfunction, acanthosis nigricans, vitamin D deficiency and osteoporosis. The causes of NAFLD are very complex, such as obesity, type 2 diabetes. With the development of Chinese society and the further improvement of people's living standards in recent years, people's daily life, working style and diet structure have also changed. The incidence of NAFLD is increasing rapidly, and it has become a common disease in the world, posing a serious threat to our health and affecting our daily life. Traditional Chinese medicine emphasizes a holistic approach and treatment based on syndrome differentiation, with multiple channels, multiple aspects, multiple levels, multiple perspectives, and minimal side effects. It has a considerable therapeutic effect in the treatment of NAFLD. This article aims to organize and summarize the research literature on Chaihu Shugan San in the treatment of NAFLD in recent years, providing reference for further clinical research and application of Chaihu Shugan San in the treatment of NAFLD.
Keywords
Chaihu Shugan San; NAFLD; research progress
Full Text
PDF - Viewed/Downloaded: 4 TimesReferences
[1]Li Junxiang, Chen Gui, Wang Yunliang. Consensus opinion on the integrated diagnosis and treatment of non-alcoholic fatty liver disease with traditional Chinese and Western medicine (2017) [J] Chinese Journal of Integrated Traditional Chinese and Western Medicine Digestive Medicine, 2017, 25(11): 805-811.
[2]Zheng Biyao, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis[J].[2024-04-01].
[3]Wang Jie, Cao Yaping, Liu Juan,et al. Research progress on the correlation between non-alcoholic fatty liver disease and gastrointestinal tumors [J] Modern Oncology Medicine, 2021, 29 (01): 149-154.
[4]Zeng Binfang, Yang Xuan, Wang Jie. Clinical progress in the treatment of non-alcoholic fatty liver with traditional Chinese medicine [J] Journal of Xinjiang Medical University, 2018, 41(02): 144-146.
[5]Gong Shimei, Shu Invention, Feng Quansheng. Research progress on the treatment of non-alcoholic fatty liver with traditional Chinese medicine compound formulas [J] Yunnan Journal of Traditional Chinese Medicine, 2016, 37(01): 83-85. DOI: 10.16254/j.cnki.53-1120/r.2016.01.039.
[6]Luo Mingchi, Xue Xiaoxue, Cheng Xufeng, et al. Clinical study on the effect of Chaihu Shugan San on inflammatory factors in non-alcoholic steatohepatitis [J] Tianjin Traditional Chinese Medicine, 2020, 37(02): 187-192.
[7]Tan Xiyang, Chen Xiaoyun, Tan Xinyi, et al. A study on the network mechanism of Chaihu Shugan San in the treatment of metabolic related fatty liver disease [J] World Science and Technology — Modernization of Traditional Chinese Medicine, 2021, 23(11): 4058-4071.
[8]Li Qin, Xie Bingxin, Jin Min, et al. Treatment of type 2 diabetes with nonalcoholic fatty liver from deficiency, depression, phlegm and blood stasis [J] Shaanxi Traditional Chinese Medicine, 2020, 41(05): 653-655.
[9]Su Wei. The clinical efficacy of Chaihu Shugan San in treating non-alcoholic fatty liver patients with liver qi stagnation type [J] Practical Clinical Practice of Integrated Traditional Chinese and Western Medicine, 2021, 21(09): 8-9. DOI: 10.13638/j.issn.1671-4040.2021.09.003.
[10]Lee T F, Lin Y L, Huang Y T. Kaerophyllin inhibits hepatic stellate cell activation by apoptotic bodies from hepatocytes[J].Liver International Official Journal of the International Association for the Study of the Liver, 2011, 31(5):618-629. DOI:10.1111/j.1478-3231.2011.02485.x.
[11]Singh P, Khosa R, Mishra G, et al. Antidiabetic activity of ethanolic extract of Cyperus rotundus rhizomes in streptozotocin-induced diabetic mice[J].Journal of Pharmacy & Bioallied Sciences, 2015, 7(4):289-292. DOI:10.4103/0975-7406.168028.
[12]SiminDai, ZhuqingLiu, Anna B.Huang, JinbaoNarsipur, NihalGuo, GraceKong, BoReuhl, KennethLu, WenyunLuo, ZishengYang, Chung S. Intake of stigmasterol and beta-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet[J].Biochimica et Biophysica Acta. Molecular and cell biology of Lipids, 2018, 1863(10).
[13]Nie H, Deng Y, Zheng C, et al. A network pharmacology‐based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors[J].Journal of Cellular and Molecular Medicine, 2020, 24(9). DOI:10.1111/jcmm.15166.
[14]Wang Dongfeng, Liang Hui, Wang Wencheng. The effect of D-limonene on lipid metabolism disorder in rats with alcoholic liver injury [J] Food Science, 2015, 36(05): 163-167.
[15]Santiago J V A, Jayachitra J, Shenbagam M, et al. Dietary d-limonene alleviates insulin resistance and oxidative stress-induced liver injury in high-fat diet and L-NAME-treated rats[J].European Journal of Nutrition, 2012, 51(1):57-68. DOI:10.1007/s00394-011-0182-7.
[16]Lei Yejing, Wang Lingling, Ye Xiaodan, et al. Clinical study on modified Chaihu Shugan San combined with polyene phosphatidylcholine capsules in the treatment of non-alcoholic steatohepatitis [J] New Traditional Chinese Medicine, 2021, 53(15): 24-28. DOI: 10.13457/j.cnki.jncm.2021.15.06.
[17]Li Dan, Jiang Tao, Fan Huaqian, et al. The effect of Chaihu Shugan San on lipid metabolism and liver function in non-alcoholic fatty liver rats [J] Pharmacology and Clinical Studies of Traditional Chinese Medicine, 2013, 29(03): 8-12. DOI: 10.13412/j.cnki.zyyl.2013.03.008.
[2]Zheng Biyao, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis[J].[2024-04-01].
[3]Wang Jie, Cao Yaping, Liu Juan,et al. Research progress on the correlation between non-alcoholic fatty liver disease and gastrointestinal tumors [J] Modern Oncology Medicine, 2021, 29 (01): 149-154.
[4]Zeng Binfang, Yang Xuan, Wang Jie. Clinical progress in the treatment of non-alcoholic fatty liver with traditional Chinese medicine [J] Journal of Xinjiang Medical University, 2018, 41(02): 144-146.
[5]Gong Shimei, Shu Invention, Feng Quansheng. Research progress on the treatment of non-alcoholic fatty liver with traditional Chinese medicine compound formulas [J] Yunnan Journal of Traditional Chinese Medicine, 2016, 37(01): 83-85. DOI: 10.16254/j.cnki.53-1120/r.2016.01.039.
[6]Luo Mingchi, Xue Xiaoxue, Cheng Xufeng, et al. Clinical study on the effect of Chaihu Shugan San on inflammatory factors in non-alcoholic steatohepatitis [J] Tianjin Traditional Chinese Medicine, 2020, 37(02): 187-192.
[7]Tan Xiyang, Chen Xiaoyun, Tan Xinyi, et al. A study on the network mechanism of Chaihu Shugan San in the treatment of metabolic related fatty liver disease [J] World Science and Technology — Modernization of Traditional Chinese Medicine, 2021, 23(11): 4058-4071.
[8]Li Qin, Xie Bingxin, Jin Min, et al. Treatment of type 2 diabetes with nonalcoholic fatty liver from deficiency, depression, phlegm and blood stasis [J] Shaanxi Traditional Chinese Medicine, 2020, 41(05): 653-655.
[9]Su Wei. The clinical efficacy of Chaihu Shugan San in treating non-alcoholic fatty liver patients with liver qi stagnation type [J] Practical Clinical Practice of Integrated Traditional Chinese and Western Medicine, 2021, 21(09): 8-9. DOI: 10.13638/j.issn.1671-4040.2021.09.003.
[10]Lee T F, Lin Y L, Huang Y T. Kaerophyllin inhibits hepatic stellate cell activation by apoptotic bodies from hepatocytes[J].Liver International Official Journal of the International Association for the Study of the Liver, 2011, 31(5):618-629. DOI:10.1111/j.1478-3231.2011.02485.x.
[11]Singh P, Khosa R, Mishra G, et al. Antidiabetic activity of ethanolic extract of Cyperus rotundus rhizomes in streptozotocin-induced diabetic mice[J].Journal of Pharmacy & Bioallied Sciences, 2015, 7(4):289-292. DOI:10.4103/0975-7406.168028.
[12]SiminDai, ZhuqingLiu, Anna B.Huang, JinbaoNarsipur, NihalGuo, GraceKong, BoReuhl, KennethLu, WenyunLuo, ZishengYang, Chung S. Intake of stigmasterol and beta-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet[J].Biochimica et Biophysica Acta. Molecular and cell biology of Lipids, 2018, 1863(10).
[13]Nie H, Deng Y, Zheng C, et al. A network pharmacology‐based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors[J].Journal of Cellular and Molecular Medicine, 2020, 24(9). DOI:10.1111/jcmm.15166.
[14]Wang Dongfeng, Liang Hui, Wang Wencheng. The effect of D-limonene on lipid metabolism disorder in rats with alcoholic liver injury [J] Food Science, 2015, 36(05): 163-167.
[15]Santiago J V A, Jayachitra J, Shenbagam M, et al. Dietary d-limonene alleviates insulin resistance and oxidative stress-induced liver injury in high-fat diet and L-NAME-treated rats[J].European Journal of Nutrition, 2012, 51(1):57-68. DOI:10.1007/s00394-011-0182-7.
[16]Lei Yejing, Wang Lingling, Ye Xiaodan, et al. Clinical study on modified Chaihu Shugan San combined with polyene phosphatidylcholine capsules in the treatment of non-alcoholic steatohepatitis [J] New Traditional Chinese Medicine, 2021, 53(15): 24-28. DOI: 10.13457/j.cnki.jncm.2021.15.06.
[17]Li Dan, Jiang Tao, Fan Huaqian, et al. The effect of Chaihu Shugan San on lipid metabolism and liver function in non-alcoholic fatty liver rats [J] Pharmacology and Clinical Studies of Traditional Chinese Medicine, 2013, 29(03): 8-12. DOI: 10.13412/j.cnki.zyyl.2013.03.008.
Copyright © 2024 Xiaoyu Gou, Feng Huang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License